17 Aug '22
Eargo Supports Over-the-Counter Hearing Aid Final Ruling
Company Applauds FDA for Increased Access, Innovation SAN JOSE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc.  (Nasdaq: EAR) (“Eargo” or the “Company”), a medical device company on a mission to improve hearing health, announced its support of the new regulatory category of over-the-counter
PDF Version
08 Aug '22
Eargo Reports Second Quarter 2022 Financial Results
Financing Update: Strengthened financial position with up to $125 million strategic investment from Patient Square Capital (the “Note Transaction”); closed first tranche investment of $100 million senior secured convertible notes on June 28, 2022 Company intends to seek stockholder approval to
PDF Version
31 May '22
Nasdaq Confirms Continued Listing of Eargo Stock
SAN JOSE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device company on a mission to improve the quality of life of people with hearing loss, announced today that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated May
PDF Version
13 May '22
Eargo Announces Receipt of Nasdaq Non-Compliance Letter
SAN JOSE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the Company received a letter (the “Letter”) from The Nasdaq Stock Market LLC
PDF Version
29 Apr '22
Eargo Provides Business Update
Reached settlement agreement to resolve DOJ investigation Company to Hold Conference Call and Web Cast on May 2, 2022 at 8 a.m. Eastern Time SAN JOSE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company”), a medical device company on a mission to improve the quality
PDF Version
Displaying 1 - 10 of 14